A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma-Reference-Cited by-同舟云学术

A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma

Published:2017-02-03 Issue:2 Volume:12 Page:e0171205
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wichert Stina,Juliusson Gunnar,Johansson Åsa,Sonesson Elisabeth,Teige Ingrid,Wickenberg Anna Teige,Frendeus Björn,Korsgren Magnus,Hansson Markus

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. Smoldering Multiple-Myeloma;RA Kyle;New Engl J Med,1980

2. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations;J Blade;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2010

3. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma;RA Kyle;New Engl J Med,2007

4. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma;RA Kyle;Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK,2009

5. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management;N Maciocia;Hematological oncology,2016

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review;The Oncologist;2024-09-05

2. Intercellular adhesion molecule-1 suppresses TMZ chemosensitivity in acquired TMZ-resistant gliomas by increasing assembly of ABCB1 on the membrane;Drug Resistance Updates;2024-09

3. Therapeutic Targeting Tongue Squamous Cell Carcinoma via ICAM1 Antibody‐Drug Conjugates in Preclinical Models;Advanced Therapeutics;2024-07

4. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma;Expert Review of Anticancer Therapy;2024-05-26

5. Age-dependent loss of HAPLN1 erodes vascular integrity via indirect upregulation of endothelial ICAM1 in melanoma;Nature Aging;2024-03-12